Caloglu M, Yurut-Caloglu V, Karagol H, Bayir-Angin G, Turan F N, Uzal C
Department of Radiation Oncology, Trakya University Hospital, Edirne, Turkey.
J BUON. 2009 Apr-Jun;14(2):211-8.
To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic factors influencing survival.
Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed.
Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT. The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators.
This study emphasizes the importance of female gender, dose and duration of RT, and RT waiting time in patients with glioblastoma multiforme.
评估多形性胶质母细胞瘤（GBM）患者的生存率，并分析影响生存率的预后因素。
回顾性分析了1999年至2006年间连续接受放疗（RT）和替莫唑胺（TMZ）治疗（21例患者）的78例GBM患者。
67例（85.5%）患者在放疗前接受了全切除或次全切除。中位总生存期为9.8个月，单因素分析显示其受年龄（p = 0.02）、卡诺夫斯基功能状态（p = 0.001）、放疗（p < 0.0001）、性别（p = 0.02）、同步使用替莫唑胺（p = 0.003）、放疗等待时间（p = 0.014）和治疗时间（p = 0.01）的显著影响。多因素分析显示，年龄较大（p = 0.03）、男性（p = 0.01）、未同步使用替莫唑胺（p = 0.008）、放疗剂量低于60 Gy（p = 0.03）、放疗等待时间超过20天（p = 0.01）以及治疗时间超过76天（p = 0.0072）是不良预后因素。
本研究强调了性别、放疗剂量和持续时间以及放疗等待时间在多形性胶质母细胞瘤患者中的重要性。
